Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting
José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Martin Dreyling(German Cancer Research Center), Steven Le Gouill(Inserm), Mats Jerkeman(Skåne University Hospital), Suzy Van Sanden(Janssen (Belgium)), Christoph Tapprich(Johnson & Johnson (Germany)), Asad Husain, Sanjay Deshpande(Janssen (United States)), Joris Diels(Janssen (Belgium)), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Malalatiana Be Harvel(Janssen (United Kingdom))
Cited by 2
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569